mecamylamine has been researched along with Anxiety in 29 studies
Mecamylamine: A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.
Anxiety: Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Clinical evidence suggests that nicotine reduces anxiety in stressful situations." | 7.74 | Acute effects of nicotine on restraint stress-induced anxiety-like behavior, c-Fos expression, and corticosterone release in mice. ( Chan, MH; Chen, HH; Chen, TY; Hsu, HR, 2007) |
| "The anxiolytic effects of aniracetam have not been proven in animals despite its clinical usefulness for post-stroke anxiety." | 7.71 | Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. ( Kurasawa, M; Nakamura, K, 2001) |
| " Preclinical research is imperative for understanding the addictive properties and health-risks associated with ECIG use; however, there is not a standard dosing regimen used across research laboratories." | 5.62 | Nicotine-free vapor inhalation produces behavioral disruptions and anxiety-like behaviors in mice: Effects of puff duration, session length, sex, and flavor. ( Allen, N; Barraza, AG; Dewey, M; Garrett, PI; Hillhouse, TM; Honeycutt, SC; Marston, C; Peterson, AM; Turner, B, 2021) |
| " To limit the potential adverse effects of alteration in cholinergic and nitric oxide (NO) systems, we investigated the combined efficacy of subthreshold doses of nAChR antagonist mecamylamine and NO ligands (L-arginine as agonist and l-NAME as an antagonist) on depression- and anxiety-related behaviors in male NMRI mice." | 3.96 | Better antidepressant efficacy of mecamylamine in combination with L-NAME than with L-arginine. ( Ebrahimi-Ghiri, M; Mohammadi-Mahdiabadi-Hasani, MH; Nasehi, M; Zarrindast, MR, 2020) |
| " All mice were then, 96 hr later, challenged with mecamylamine (3 mg/kg), and tested for anxiety-like behaviors 30 min later." | 3.96 | The role of pituitary adenylyl cyclase activating polypeptide in affective signs of nicotine withdrawal. ( Ahmad, SM; Hamid, A; Lutfy, K; Marquez, P; Nega, S, 2020) |
| " We analysed the time course of the global withdrawal score, the anxiety-like effects, monoamine concentrations, the brain-derived neurotrophic factor (BDNF) expression, the corticosterone plasmatic levels and [(3)H]epibatidine binding sites during NIC withdrawal precipitated by mecamylamine, a nicotinic receptor antagonist (MEC)." | 3.81 | Lack of GABAB receptors modifies behavioural and biochemical alterations induced by precipitated nicotine withdrawal. ( Antonelli, MC; Balerio, GN; Bettler, B; Machado, LM; Pedrón, VT; Varani, AP, 2015) |
| "Clinical evidence suggests that nicotine reduces anxiety in stressful situations." | 3.74 | Acute effects of nicotine on restraint stress-induced anxiety-like behavior, c-Fos expression, and corticosterone release in mice. ( Chan, MH; Chen, HH; Chen, TY; Hsu, HR, 2007) |
| "The anxiolytic effects of aniracetam have not been proven in animals despite its clinical usefulness for post-stroke anxiety." | 3.71 | Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. ( Kurasawa, M; Nakamura, K, 2001) |
| "Dorsal hippocampal cholinergic modulation of behavior in different tests of anxiety was investigated by direct injection of the muscarinic M1 and M2 receptor antagonists, pirenzepine and gallamine, and the nicotinic receptor antagonist mecamylamine." | 3.70 | Endogenous acetylcholine in the dorsal hippocampus reduces anxiety through actions on nicotinic and muscarinic1 receptors. ( Andrews, N; File, SE; Gonzalez, LE, 1998) |
| "In the present study, the effect of alpha-adrenoceptor agents on response to nicotine in an anxiety model (elevated plus-maze) in mice was investigated." | 3.70 | Involvement of adrenergic and cholinergic systems in nicotine-induced anxiogenesis in mice. ( Babaie, A; Etminani, A; Gharib, B; Homayoun, H; Zarrindast, MR, 2000) |
| " Preclinical research is imperative for understanding the addictive properties and health-risks associated with ECIG use; however, there is not a standard dosing regimen used across research laboratories." | 1.62 | Nicotine-free vapor inhalation produces behavioral disruptions and anxiety-like behaviors in mice: Effects of puff duration, session length, sex, and flavor. ( Allen, N; Barraza, AG; Dewey, M; Garrett, PI; Hillhouse, TM; Honeycutt, SC; Marston, C; Peterson, AM; Turner, B, 2021) |
| "Nicotine treatment increased ACh levels to a larger extent in females than males." | 1.51 | Sex differences in cholinergic systems in the interpeduncular nucleus following nicotine exposure and withdrawal. ( Arreguin, MC; Carcoba, LM; Correa, VL; Flores, RJ; O'Dell, LE, 2019) |
| "The nicotine plasma levels were also measured with or without methoxsalen pretreatment." | 1.40 | Effects of methoxsalen, a CYP2A5/6 inhibitor, on nicotine dependence behaviors in mice. ( Bagdas, D; Damaj, MI; Muldoon, PP; Tyndale, RF; Zhu, AZ, 2014) |
| "Nicotine dependence was induced via osmotic minipump in adolescent rats (releasing 22." | 1.33 | Withdrawal from chronic nicotine in adolescent and adult rats. ( Spear, LP; Wilmouth, CE, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (6.90) | 18.2507 |
| 2000's | 13 (44.83) | 29.6817 |
| 2010's | 11 (37.93) | 24.3611 |
| 2020's | 3 (10.34) | 2.80 |
| Authors | Studies |
|---|---|
| Tan, S | 1 |
| Xue, S | 1 |
| Behnood-Rod, A | 1 |
| Chellian, R | 1 |
| Wilson, R | 1 |
| Knight, P | 1 |
| Panunzio, S | 1 |
| Lyons, H | 1 |
| Febo, M | 2 |
| Bruijnzeel, AW | 2 |
| Ebrahimi-Ghiri, M | 2 |
| Mohammadi-Mahdiabadi-Hasani, MH | 1 |
| Nasehi, M | 3 |
| Zarrindast, MR | 6 |
| Nega, S | 1 |
| Marquez, P | 1 |
| Hamid, A | 1 |
| Ahmad, SM | 1 |
| Lutfy, K | 1 |
| Garrett, PI | 1 |
| Honeycutt, SC | 1 |
| Marston, C | 1 |
| Allen, N | 1 |
| Barraza, AG | 1 |
| Dewey, M | 1 |
| Turner, B | 1 |
| Peterson, AM | 1 |
| Hillhouse, TM | 1 |
| Nunes, EJ | 1 |
| Bitner, L | 1 |
| Hughley, SM | 1 |
| Small, KM | 1 |
| Walton, SN | 1 |
| Rupprecht, LE | 1 |
| Addy, NA | 1 |
| Correa, VL | 1 |
| Flores, RJ | 1 |
| Carcoba, LM | 1 |
| Arreguin, MC | 1 |
| O'Dell, LE | 2 |
| Piri, M | 1 |
| Bananej, M | 1 |
| Shahab, Z | 1 |
| Zahmatkesh, M | 1 |
| Tajik, R | 1 |
| Rezayof, A | 1 |
| Bagdas, D | 1 |
| Muldoon, PP | 1 |
| Zhu, AZ | 1 |
| Tyndale, RF | 1 |
| Damaj, MI | 1 |
| Varani, AP | 1 |
| Pedrón, VT | 1 |
| Machado, LM | 1 |
| Antonelli, MC | 1 |
| Bettler, B | 1 |
| Balerio, GN | 1 |
| Qi, X | 1 |
| Guzhva, L | 1 |
| Yang, Z | 1 |
| Shan, Z | 1 |
| Wang, KKW | 1 |
| Solati, J | 1 |
| Oryan, S | 1 |
| Parivar, K | 1 |
| Trigo, JM | 1 |
| Zimmer, A | 1 |
| Maldonado, R | 1 |
| Levin, ED | 1 |
| Roni, MA | 1 |
| Rahman, S | 1 |
| Sharifi, S | 1 |
| Wilmouth, CE | 1 |
| Spear, LP | 1 |
| Mineur, YS | 1 |
| Somenzi, O | 1 |
| Picciotto, MR | 1 |
| Hsu, HR | 1 |
| Chen, TY | 1 |
| Chan, MH | 1 |
| Chen, HH | 1 |
| George, O | 1 |
| Ghozland, S | 1 |
| Azar, MR | 1 |
| Cottone, P | 1 |
| Zorrilla, EP | 1 |
| Parsons, LH | 1 |
| Richardson, HN | 1 |
| Koob, GF | 1 |
| File, SE | 4 |
| Gonzalez, LE | 1 |
| Andrews, N | 1 |
| Ouagazzal, AM | 1 |
| Kenny, PJ | 3 |
| Cheeta, S | 2 |
| Homayoun, H | 1 |
| Babaie, A | 1 |
| Etminani, A | 1 |
| Gharib, B | 1 |
| Newman, MB | 2 |
| Nazian, SJ | 1 |
| Sanberg, PR | 2 |
| Diamond, DM | 1 |
| Shytle, RD | 2 |
| Nakamura, K | 1 |
| Kurasawa, M | 1 |
| Sienkiewicz-Jarosz, H | 1 |
| Członkowska, AI | 1 |
| Siemiatkowski, M | 1 |
| Maciejak, P | 1 |
| Szyndler, J | 1 |
| Płaźnik, A | 1 |
| Manresa, JJ | 1 |
1 review available for mecamylamine and Anxiety
| Article | Year |
|---|---|
The role of the dorsal hippocampal serotonergic and cholinergic systems in the modulation of anxiety.
Topics: Acetylcholine; Animals; Anxiety; Hippocampus; Humans; Interpersonal Relations; Maze Learning; Mecamy | 2000 |
28 other studies available for mecamylamine and Anxiety
| Article | Year |
|---|---|
Sex differences in the reward deficit and somatic signs associated with precipitated nicotine withdrawal in rats.
Topics: Animals; Anxiety; Brain; Estrous Cycle; Female; Male; Mecamylamine; Nicotine; Nicotinic Agonists; Ni | 2019 |
Better antidepressant efficacy of mecamylamine in combination with L-NAME than with L-arginine.
Topics: Animals; Animals, Outbred Strains; Antidepressive Agents; Anxiety; Arginine; Behavior, Animal; Choli | 2020 |
The role of pituitary adenylyl cyclase activating polypeptide in affective signs of nicotine withdrawal.
Topics: Animals; Anxiety; Conditioning, Psychological; Depression; Female; Male; Mecamylamine; Mice; Mice, I | 2020 |
Nicotine-free vapor inhalation produces behavioral disruptions and anxiety-like behaviors in mice: Effects of puff duration, session length, sex, and flavor.
Topics: Administration, Inhalation; Adolescent; Animals; Anxiety; Behavior, Animal; E-Cigarette Vapor; Elect | 2021 |
Cholinergic Receptor Blockade in the VTA Attenuates Cue-Induced Cocaine-Seeking and Reverses the Anxiogenic Effects of Forced Abstinence.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Cholinergic Antagonists; Cocaine-Related Disorders; Disease M | 2019 |
Sex differences in cholinergic systems in the interpeduncular nucleus following nicotine exposure and withdrawal.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Anxiety; Behavior, Animal; Female; Gene Expression | 2019 |
Evaluation of functional relationship between mouse hippocampal cholinergic and nitrergic systems in anxiogenic-like behavior.
Topics: Analysis of Variance; Animals; Anxiety; Arginine; Cholinergic Agents; Disease Models, Animal; Dose-R | 2013 |
Role of the medial septum cholinoceptors in anxiogenic-like effects of nicotine.
Topics: Animals; Anxiety; Atropine; Cholinergic Agonists; Dose-Response Relationship, Drug; Drug Interaction | 2013 |
Effects of methoxsalen, a CYP2A5/6 inhibitor, on nicotine dependence behaviors in mice.
Topics: Animals; Anxiety; Aryl Hydrocarbon Hydroxylases; Conditioning, Psychological; Cytochrome P450 Family | 2014 |
Lack of GABAB receptors modifies behavioural and biochemical alterations induced by precipitated nicotine withdrawal.
Topics: Animals; Anxiety; Brain; Brain-Derived Neurotrophic Factor; Corticosterone; Disease Models, Animal; | 2015 |
Overexpression of CRF in the BNST diminishes dysphoria but not anxiety-like behavior in nicotine withdrawing rats.
Topics: Animals; Anxiety; Corticotropin-Releasing Hormone; Dependovirus; Disease Models, Animal; Genetic Vec | 2016 |
Effect of intra-amygdala injection of nicotine and GABA receptor agents on anxiety-like behaviour in rats.
Topics: Amygdala; Animals; Anxiety; Behavior, Animal; Bicuculline; Dose-Response Relationship, Drug; GABA Ag | 2008 |
Nicotine anxiogenic and rewarding effects are decreased in mice lacking beta-endorphin.
Topics: Animals; Anxiety; beta-Endorphin; Conditioning, Classical; Crosses, Genetic; Exploratory Behavior; F | 2009 |
Zebrafish assessment of cognitive improvement and anxiolysis: filling the gap between in vitro and rodent models for drug development.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Attention; Buspirone; Disease Models, Animal; Dose-Response R | 2011 |
Neuronal nicotinic receptor antagonist reduces anxiety-like behavior in mice.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Blood-Brain Barrier; Brain; Exploratory Behavior; Hexamethoni | 2011 |
Involvement of the cholinergic system of CA1 on harmane-induced amnesia in the step-down passive avoidance test.
Topics: Amnesia; Animals; Anxiety; Avoidance Learning; CA1 Region, Hippocampal; Cholinergic Fibers; Dose-Res | 2012 |
Withdrawal from chronic nicotine in adolescent and adult rats.
Topics: Age Factors; Animals; Anxiety; Body Weight; Male; Maze Learning; Mecamylamine; Rats; Rats, Sprague-D | 2006 |
Cytisine, a partial agonist of high-affinity nicotinic acetylcholine receptors, has antidepressant-like properties in male C57BL/6J mice.
Topics: Alkaloids; Animals; Antidepressive Agents; Anxiety; Azocines; Brain; Depression; Feeding Behavior; G | 2007 |
Acute effects of nicotine on restraint stress-induced anxiety-like behavior, c-Fos expression, and corticosterone release in mice.
Topics: Animals; Anxiety; Behavior, Animal; Brain; Corticosterone; Male; Mecamylamine; Mice; Mice, Inbred St | 2007 |
CRF-CRF1 system activation mediates withdrawal-induced increases in nicotine self-administration in nicotine-dependent rats.
Topics: Amygdala; Animals; Anxiety; Behavior, Addictive; Behavior, Animal; Corticotropin-Releasing Hormone; | 2007 |
Endogenous acetylcholine in the dorsal hippocampus reduces anxiety through actions on nicotinic and muscarinic1 receptors.
Topics: Acetylcholine; Analysis of Variance; Animals; Anti-Anxiety Agents; Anxiety; Catheterization; Explora | 1998 |
Stimulation of nicotinic receptors in the lateral septal nucleus increases anxiety.
Topics: Animals; Anxiety; Brain Mapping; Dose-Response Relationship, Drug; Male; Maze Learning; Mecamylamine | 1999 |
Neurobiological mechanisms by which nicotine mediates different types of anxiety.
Topics: Animals; Anxiety; Hippocampus; Interpersonal Relations; Maze Learning; Mecamylamine; Nicotine; Nicot | 2000 |
Involvement of adrenergic and cholinergic systems in nicotine-induced anxiogenesis in mice.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Anxiety; Atropine; Clonidine; Hexa | 2000 |
Corticosterone-attenuating and anxiolytic properties of mecamylamine in the rat.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Cats; Corticosterone; Dose-Response Relationship, Drug; Hypot | 2001 |
Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Bro | 2001 |
The effects of physostigmine and cholinergic receptor ligands on novelty-induced neophobia.
Topics: Animals; Anxiety; Cerebral Ventricles; Cholinergic Agonists; Cholinesterase Inhibitors; Exploratory | 2000 |
Anxiolytic effects of mecamylamine in two animal models of anxiety.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Interpersonal Relations; Lighting; Male; Me | 2002 |